You are here

FDA Approves Desogestrel and Ethinyl Estradiol Tablets

CORONA, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) , a leading specialty pharmaceutical company, announced today that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application for desogestrel and ethinyl estradiol tablets USP, 0.15mg / 0.03mg, a generic version of Ortho-McNeil's Ortho-Cept(R) and Organon's Desogen(R) products which are indicated for the prevention of pregnancy.

The Company intends to initiate shipments of the product immediately. For the 12-months ending March 2005, desogestrel and ethinyl estradiol tablets USP, 0.15mg / 0.03mg market had total U.S. sales of approximately $180 million, according to IMS Health data.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs